Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 5/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118389 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL3871700 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL30440863 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL29989314 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL13940186 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL29824809 | 1.00 | MDM4 (0.52) | MDM4TP53CASP1CASP3KMT2A | |
| SCHEMBL5967446 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL119637 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29455664 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL119688 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695268-A1 | ANTIBACTERIAL COVALENT PEPTIDE INHIBITORS | Université de Bordeaux (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20260000784-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | HOSPITAL SANT JOAN DE DEU (ES) | 2026-01-01 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4565281-A1 | SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER | Gate2Brain, S.L. (ES) | 2025-06-11 | — | — | EP | disclosed |
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115232196-B | Polypeptide inhibitor for treating triple negative breast cancer and preparation method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2025-03-28 | — | — | CN | disclosed |
| CN-119552215-A | Tumor targeting polypeptides, conjugates comprising same, compositions and uses | 苏州星洲生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4499150-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | Hospital Sant Joan de Deu (ES) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024211999-A9 | EXTRACELLULAR HSP90 (EHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2025-01-16 | — | — | WO | disclosed |
| EP-4046996-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universität Bielefeld (DE) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022162332-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-08-04 | — | — | WO | disclosed |
| CN-109912686-B | Stable polypeptide inhibitor targeting HDAC (Histone deacetylase) and application thereof | 北京大学深圳研究生院 | 2022-07-05 | — | — | CN | disclosed |
| US-11353448-B2 | Methods and compositions for quantifying metabolites and proteins from single cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-07 | — | — | US | disclosed |
| CN-111690041-B | Polypeptide with anti-tumor activity and preparation method thereof | 上海大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-114437181-A | GLP-1R/GCGR/GIPR triple receptor agonist and application thereof | 深圳深创生物药业有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022064052-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-31 | — | — | WO | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | PALATIN TECHNOLOGIES INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MDM4 4380/4885TP53 3497/4885CASP1 515/4885 |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | MC3R, GIPR, MC1R | MDM4 4773/4885TP53 3820/4885CASP1 4408/4885 |
| US-20260000784-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | TP53, SGMS1, ABCB11 | MDM4 1734/4885TP53 1/4885CASP1 690/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | MDM4 2510/4885TP53 112/4885CASP1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.